Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$6.52 USD
+0.38 (6.19%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $6.55 +0.03 (0.46%) 7:56 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SYRS 6.52 +0.38(6.19%)
Will SYRS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SYRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SYRS
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates
Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know
SYRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for
Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Other News for SYRS
TD Cowen Keeps Their Buy Rating on Syros Pharmaceuticals (SYRS)
Buy Rating Affirmed: Syros Pharmaceuticals’ Promising Tamibarotene for MDS Treatment
JMP Securities Reaffirms Their Buy Rating on Syros Pharmaceuticals (SYRS)
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
Syros Pharmaceuticals’ Shareholders Approve Key Updates and Elections